NewsDialy
The scientific leader of a genetic medicines division has changed. Genetic medicines, in plain terms, is the field of therapies that act on DNA or RNA to treat disease at its source.
Alloy Therapeutics is the company gaining a new leader in this space: Venkat Krishnamurthy, who joins as chief scientific officer of its genetic medicines division.
He previously held the same title at Flashpoint Therapeutics. Details about his work at Flashpoint, and the specifics of Alloy's pipeline in this field, are not available from current disclosures.
The short version: a scientist who already held the chief scientific officer title at one company has moved into the same role at another, now leading Alloy Therapeutics' genetic medicines effort.
Keep reading